Markoczy Z,; Sárosi, Veronika; Kudaba I,; Gálffy, Gabriella; Turay UY,; Demirkazik A; Purkalne G; Somfay, Attila; Papai-Szekely Z; Rásó, Erzsébet; Ostoros G
(2018)
BACKGROUND: Erlotinib is approved for the first line treatment of epidermal growth factor receptor (EGFR) mutation-positive non-small cell lung cancer. Since the number of prospective studies in Caucasian patients treated ...